- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 30.10. | Investors put $115M into Axonis amid revived interest in brain drugs | ||
| 30.10. | Biogen, Sage admit a defeat in major depression | ||
| 30.10. | Biogen optimistic as new products gain traction | ||
| 30.10. | Lilly shares fall as obesity drug sales miss forecasts | ||
| 30.10. | A new biotech, built around protein design, springs from David Baker's lab | ||
| 29.10. | Pfizer sales of RSV vaccine ebb, but company gains market share | ||
| 29.10. | Paragon spinout joins hunt for new type of cancer immunotherapy | ||
| 29.10. | GSK to pay $300M to license drug it sees as potential lupus treatment | ||
| 29.10. | Biogen refreshes its C-suite; Novartis writes down MorphoSys assets | ||
| 29.10. | Pfizer answers Starboard challenge with beat-and-raise quarter | ||
| 28.10. | AbbVie to acquire a J&J-backed brain drugmaker for $1.4B | ||
| 28.10. | Monte Rosa joins with Novartis in 'molecular glue' drug deal | ||
| 28.10. | After Pfizer deal, former Seagen CEO returns to lead oncology startup | ||
| 28.10. | With new diversity guidance, EHR data plus AI will be critical | ||
| 28.10. | How pharmaceutical companies can leverage print to remain agile and competitive | ||
| 28.10. | Don't let your samples slip: Why every clinical trial needs biospecimen management | ||
| 25.10. | Sanofi earnings boosted by Beyfortus, earlier vaccine sales | ||
| 25.10. | GSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilar | ||
| 25.10. | GPCR drugmaker Septerna amasses $288M in IPO | ||
| 25.10. | Lyell, in search of a turnaround, to buy cell therapy startup ImmPact | ||
| 24.10. | Merck, Pfizer lifted as CDC backs broader use of pneumococcal vaccines | ||
| 24.10. | Intellia data spark debate about CRISPR drug's potential | ||
| 24.10. | Dengue is spreading and Sanofi is pulling the market's only vaccine. What's next? | ||
| 24.10. | J&J's Asish Xavier on biotech's rebound in a volatile era | ||
| 23.10. | Alto hits new low as depression drug flunks key test |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
